Skip to main content
. 2023 Mar 15;18(11):2474–2481. doi: 10.4103/1673-5374.371377

Figure 1.

Figure 1

Liproxstatin-1 reduces blood-spinal cord barrier disruption after SCI.

(A) Experimental design of the analysis of liproxstatin-1 (Lip-1) in blood-spinal cord barrier protection after SCI. Evans blue was injected through the tail vein 3 days after SCI. Spinal cord tissues were removed after 3 hours. (B) The leakage of Evans blue at the lesion site of rats in each group at 3 days post-SCI (n = 3). Scale bar:5 mm. (C) Representative fluorescent images of Evans blue leak (red) at the epicenter and rostral and caudal regions. Scale bar: 50 µm. Dotted circles indicate the outline of the transverse section of the spinal cord tissue. (D) Statistical analysis of Evans blue leakage (n = 3). (E) Representative immunofluorescence images of zonula occludens-1 (ZO-1; green) and rat endothelium cell antigen-1 (RECA-1; red) staining and cell nuclei (blue) at 3 days after SCI. Scale bars: 200 µm and 20 µm (in magnified figures). Boxes represent the magnified region. (F) Quantitative analysis of the relative fluorescence intensity of ZO-1 in RECA-1+ area (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001. Data were analyzed with one-way analysis of variance followed by Tukey’s post hoc test. SCI: Spinal cord injury.